102308-68-9

Usage

Uses

Used in Organic Synthesis:
2H-Benzimidazol-2-one,1,3-dihydro-4,6-dimethyl-(9CI) is used as a building block in organic synthesis for the preparation of pharmaceuticals and other biologically active compounds. Its unique structure allows for the creation of a wide range of molecules with diverse properties and potential applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2H-Benzimidazol-2-one,1,3-dihydro-4,6-dimethyl-(9CI) is utilized as a starting material for the development of new drugs. Its potential applications include the treatment of various diseases and conditions, making it a valuable component in the search for novel therapeutic agents.
Used in the Synthesis of Nitrogen-Containing Heterocycles:
Furthermore, 2H-Benzimidazol-2-one,1,3-dihydro-4,6-dimethyl-(9CI) can be used as a starting material for the synthesis of other nitrogen-containing heterocycles with potential pharmaceutical properties. This expands its utility in the development of new compounds with therapeutic potential, contributing to the advancement of medicinal chemistry and drug discovery.

Upstream product

• 75-44-5 phosgene 
• 3171-46-8 3,5-dimethylbenzene-1,2-diamine 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 942220-47-5 methyl 2-iodo-4,6-dimethylphenylcarbamate 
• 1635-84-3 2,4-Dimethyl-6-nitroanilin 

Relevant academic research and scientific papers

Assembly of substituted 1H-benzimidazoles and 1,3-dihydrobenzimidazol-2- ones via CuI/L-proline catalyzed coupling of aqueous ammonia with 2-iodoacetanilides and 2-iodophenylcarbamates

(Chemical Equation Presented) CuI/L-proline catalyzed coupling of aqueous ammonia with 2-iodoacetanilides and 2-iodophenylcarbamates affords the aryl amination products at room temperature, which undergo in situ additive cyclization under acidic conditions or heating to give substituted 1H-benzimidazoles and 1,3-dihydrobenzimidazol-2-ones, respectively. A wide range of functional groups including ketone, nitro, iodo, bromo, and ester are tolerated under these reaction conditions, providing these heterocycles with great diversity.

BICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: I (wherein variables A1, A2, B, m, n, J, R4, G1, G2, G3 and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

BICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds of Formula (I): (where variables A1, A2, B, J, K, m, n, R4, R5a, R5b and R5c are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.